This setback has led to renewed efforts to understand cancer immune resistance mechanisms and to explore alternative strategies, such as enhancing Kyn degradation through enzymes like kynureninase [15,77] or blockage of AhR receptor [78], which have shown promising preclinical results in reducing tumor burden and prolonging survival. Here, KYNU is linked to neoplasm.